Jones Financial Companies Lllp Grows Stake in Elevance Health, Inc. $ELV

Jones Financial Companies Lllp increased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 38.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 67,769 shares of the company’s stock after acquiring an additional 18,939 shares during the period. Jones Financial Companies Lllp’s holdings in Elevance Health were worth $21,643,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Activest Wealth Management increased its holdings in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. acquired a new position in shares of Elevance Health during the 2nd quarter worth approximately $32,000. Motco lifted its stake in Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. Finally, True Wealth Design LLC grew its holdings in Elevance Health by 431.8% during the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ELV. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Jefferies Financial Group lowered their price target on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. Finally, Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Price Performance

ELV opened at $338.66 on Wednesday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The company’s 50 day simple moving average is $351.99 and its 200 day simple moving average is $329.59. The stock has a market capitalization of $75.26 billion, a PE ratio of 13.48, a P/E/G ratio of 1.90 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health’s payout ratio is 27.23%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: JPMorgan raised its price target slightly from $394 to $397 and maintained an “overweight” rating, which supports upside vs. the current price. Read More.
• Neutral Sentiment: Options-market activity is drawing attention — some traders see positioning that could presage larger moves, but this is speculative and not a direct fundamental change. Read More.
• Neutral Sentiment: Seeking Alpha published a long-form take (“It Has Been Painful, But This Too Shall Pass”) arguing the near-term weakness is cyclical and could reverse — useful for longer-term investors but less likely to move stock intraday. Read More.
• Neutral Sentiment: The Globe and Mail aggregated analyst commentary on multiple healthcare names including Elevance; helpful context but no single decisive call. Read More.
• Negative Sentiment: RBC downgraded ELV from “outperform” to “sector perform” and set a $358 target — a downgrade in stance that likely pressured sentiment despite a modestly positive target. Read More.
• Negative Sentiment: Truist trimmed its price target from $400 to $390 while keeping a “buy” rating — the lower target reduces upside expectations and can weigh on the stock. Read More.
• Negative Sentiment: Jefferies cut its price target to $395, another downward revision that adds to the negative analyst tone. Read More.
• Negative Sentiment: Sanford C. Bernstein lowered its target to $409 — still above the current price but a cut nonetheless, contributing to the cluster of downward revisions. Read More.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.